Royalty Pharma Partners with Biogen to Develop Litifilimab
Shots:
- Royalty Pharma & Biogen have entered into an agreement for the clinical development of litifilimab in SLE & CLE
- As per the agreement, Biogen will receive ~$250M R&D funding over 6 quarters to support the development, whereas Royalty Pharma is entitled to receive regulatory milestones & mid-single digit royalties on global sales
- Litifilimab (anti-BDCA2 mAb) is being investigated in P-III trials for both SLE & CLE with results expected in 2026-2027, while PoC data of distinct MoA & safety is published in The NEJM
Ref: Royalty Pharma | Image: Royalty Pharma & Biogen
Related News:- Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
